Complete remissions have been achieved in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) by CD19-targeting CAR T-cells [1–4]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.